Stifel analyst Daniel Arias lowered the firm’s price target on Bruker (BRKR) to $40 from $48 and keeps a Hold rating on the shares. The company’s Q2 miss and revised outlook “featured a combination of both expected and unexpected factors,” the analyst tells investors. The EPS guidance reset “should clear the deck on 2025 earnings,” and “there will come a time again to own” the stock, but in the firm’s view “we’re not there yet,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker Corporation Reports Q2 2025 Financial Results
- Bruker: Strategic Cost-Saving Initiatives and Margin Expansion Justify Buy Rating Despite Market Challenges
- Bruker Hold Rating: Downward Guidance Revision and Weak Demand Trends Prompt Cautious Outlook
- Bruker price target lowered to $38 from $40 at Citi
- Bruker price target lowered to $43 from $46 at Barclays